We assessed variables associated with survivorship care outcomes in an incident cohort of 5014 commercially insured women under age 65 years, newly diagnosed with stage I or II hormone receptor positive, human epidermal growth factor receptor 2 HER2 non positive breast cancer from 2006 to 2010 stromectol prescribing information